Evidence map›Paper›PMID 39988439›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2025

[Exploration and Challenge of Whole Course Follow-up Management Model 
for Small Cell Lung Cancer].

Chengming Huang, Yongzhao Zhou, Jing Xu, Wenting Lu, Li Tu, Yalun Li, Panwen Tian

Abstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chengming HuangIntegrated Care Management Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Yongzhao ZhouIntegrated Care Management Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Jing XuIntegrated Care Management Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Wenting LuIntegrated Care Management Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Li TuLung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Yalun LiDepartment of Respiratory and Critical Care Medicine, 
West China Hospital, Sichuan University, Chengdu 610041, China.
Panwen TianLung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small cell lung cancer (SCLC) is a highly malignant disease that has garnered significant attention in terms of treatment modalities and course management. Gaining an understanding of the clinical characteristics of SCLC, acquiring proficiency in screening, diagnosis, and treatment methods for this condition, as well as promptly addressing any adverse reactions to treatment are essential foundations for developing a scientific and rational pathological management plan for SCLC. By utilizing an intelligent whole course follow-up management platform, dynamic follow-up, timely warnings, and early interventions can enable high-quality whole life cycle management. This article aims to review the current treatment landscape of SCLC while exploring the challenges associated with implementing a comprehensive process-oriented management approach. The goal is to provide valuable insights for better managing SCLC patients and ultimately improving their quality of life and prognosis.
.

Indexed as

Lung NeoplasmsSmall Cell Lung CarcinomaFollow-Up StudiesHumansQuality of LifeExploration and challengeLung neoplasmsSmall cell lung cancerWhole course management

Identifiers

PMID39988439
PMCPMC11848691

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.